Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
im-1021
- Development stage
- Phase 1
- Lead developer
- Immunome
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IM-1021 is a ROR1-targeted antibody-drug conjugate (ADC) developed by Immunome for the treatment of advanced B-cell lymphomas and solid tumors. The drug consists of a monoclonal antibody directed against receptor tyrosine kinase-like orphan receptor 1 (ROR1), conjugated via a cleavable linker to HC74, Immunome’s proprietary camptothecin-derived DNA topoisomerase I (TOP1) inhibitor payload. This design aims to maximize internalization and the bystander effect in tumor cells with variable ROR1 expression. IM-1021 is currently being evaluated in Phase 1 clinical trials for safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with high unmet medical need[1][3][5][6]. Preclinical data have shown robust anti-tumor activity across multiple models including mantle cell lymphoma and triple-negative breast cancer[2][4].
- Other names
- ZPC-21ZPC21ZPC 21
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on im-1021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on im-1021.